The world's #1 cause of
irreversible blindness

ABOUT GLAUCOMA
Glaucoma, a group of eye diseases that can result in optic nerve damage and irreversible blindness, is one of the most vexing issues in healthcare, affecting 60–80 million people globally.
grafic lines 4

What Causes Glaucoma?

The exact cause of optic nerve damage from glaucoma is not fully understood, but high eye pressure is most often associated with the disease. High intraocular pressure (IOP) left untreated may result in irreversible optic nerve damage that can ultimately lead to blindness.
A healthy eye drains continuously and without obstruction
Blockages in the natural drainage system can develop, increasing intraocular pressure
A life-long eye disease called Glaucoma develops, which can cause irreversible vision loss

The Varying Types of Glaucoma

MAIN TYPES

The two main types of glaucoma are open-angle glaucoma and angle-closure glaucoma. Each is most commonly marked by an increase of pressure inside the eye.

In angle-closure glaucoma, the drainage angle between the iris and the cornea becomes closed/narrow which blocks fluid from exiting the eye and results in a significant rise in IOP.

In contrast, in open-angle glaucoma, the angle between the iris and the cornea is as wide and open as it should be, but the outflow pathway can become compromised over time, causing an increase in IOP.

Of the two types, open-angle glaucoma is the most common form of glaucoma.

Sight Sciences' surgical systems are intended to lower pressure in patients suffering from open-angle glaucoma, the most common form of glaucoma that accounts for 90% of all cases*.

grafic lines 4

Current Treatment Options

There is no cure for glaucoma, but there are several treatments intended to reduce the intraocular pressure associated with the disease.
The cost and burden of such treatment methods, which may involve a complicated and costly dosing regimen with multiple eyedrops or highly invasive surgery, have driven the development of novel, less invasive surgical approaches. Glaucoma treatment can vary as the disease progresses. More recently, less invasive glaucoma devices have been approved that can be either delivered or allow for procedures through only a single, sutureless corneal incision and may slow the progression of disease, delay the need for a more invasive surgery, and often reduce the medication burden for patients.
MILD
Eye Drops

The most common treatment for mild glaucoma is prescription eye drops. However, studies show that at least 50% of patients are not compliant with their medications within 6 months of diagnosis. 1

SLT Laser

SLT may be used in mild-moderate glaucoma as an alternative to prescription eye drops, or in an effort to reduce the medication burden. The effectiveness of laser treatment is known to diminish over a period of months or years.

MODERATE
Microinvasive Glaucoma Interventions

In contrast to the current options of daily eye drops or highly invasive surgery, Sight Sciences has developed an innovative and minimally invasive glaucoma surgical system designed to restore natural aqueous outflow and reduce IOP.

ADVANCED
Combined Micro-Invasive Glaucoma Surgery (MIGS) Procedure

In contrast to the current options of daily eye drops or highly invasive surgery, Sight Sciences has developed an innovative and minimally invasive glaucoma surgical system designed to restore natural aqueous outflow and reduce IOP.

END-STAGE
Filtering Surgery + Tube Shunt

To mitigate the progression of the disease and subsequent loss of vision, end-stage glaucoma patients undergo highly invasive filtering surgery that may include implantation of tube shunts.

Learn more about Sight Sciences' novel, minimally invasive glaucoma surgery system.

VISIT OMNI WEBSITE
Thank You

We appreciate your interest in Sight Sciences and our products. A member of our team will review your inquiry and follow up with you during business hours.

Disclamer

In providing these materials requested by you, the physician, Sight Sciences does not intend to support or endorse any presentations, communications, or other messages you may impart through the use of these materials.

If and when you use the materials in a presentation, communication, or other message, please include a disclaimer that the statements and opinions in the presentation/communication/message are entirely your own and are not supported or endorsed by Sight Sciences.

Accept decline
Indications and Safety for OMNI® Surgical System

Indications for use

The OMNI® Glaucoma Treatment System is indicated for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

Contraindications

1. Do not use the OMNI in any situations where the angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.
2. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

Warnings

1. Do not use in cases where there is insufficient visibility to properly see the angle. The following conditions may prohibit sufficient visualization of the angle required for safe and successful cannula placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the angle and intended cannula entry location.
2. Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.
3. Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.

Potential adverse events

Adverse events that may be reasonably associated with the use of the OMNI™ System in the eye include but are not limited to the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation including toxic anterior segment syndrome (TASS), endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including but not limited to glaucoma surgery, and vitreous hemorrhage.